Estrella Retained Earnings from 2010 to 2024

ESLAW Stock   0.09  0.0008  0.89%   
Estrella Immunopharma Retained Earnings yearly trend continues to be fairly stable with very little volatility. Retained Earnings are likely to outpace its year average in 2024. Retained Earnings is the cumulative amount of net income that Estrella Immunopharma retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals
 
Retained Earnings  
First Reported
2010-12-31
Previous Quarter
-19.5 M
Current Value
-18.5 M
Quarterly Volatility
6.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Estrella Immunopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Estrella Immunopharma's main balance sheet or income statement drivers, such as Tax Provision of 1.7 K, Depreciation And Amortization of 246.2 K or Selling General Administrative of 3.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 8.39. Estrella financial statements analysis is a perfect complement when working with Estrella Immunopharma Valuation or Volatility modules.
  
Check out the analysis of Estrella Immunopharma Correlation against competitors.
For more information on how to buy Estrella Stock please use our How to Invest in Estrella Immunopharma guide.

Latest Estrella Immunopharma's Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Estrella Immunopharma over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Estrella Immunopharma's Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Estrella Immunopharma's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (19.5 M)10 Years Trend
Slightly volatile
   Retained Earnings   
       Timeline  

Estrella Retained Earnings Regression Statistics

Arithmetic Mean(2,757,034)
Geometric Mean0.00
Coefficient Of Variation(240.53)
Mean Deviation4,334,863
Median0.00
Standard Deviation6,631,473
Sample Variance44T
Range19.5M
R-Value(0.63)
Mean Square Error28.5T
R-Squared0.40
Significance0.01
Slope(936,622)
Total Sum of Squares615.7T

Estrella Retained Earnings History

2024-18.5 M
2023-19.5 M
2022-2.3 M
2021-1.1 M

About Estrella Immunopharma Financial Statements

Estrella Immunopharma investors use historical fundamental indicators, such as Estrella Immunopharma's Retained Earnings, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Estrella Immunopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Retained Earnings-19.5 M-18.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Estrella Stock Analysis

When running Estrella Immunopharma's price analysis, check to measure Estrella Immunopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Estrella Immunopharma is operating at the current time. Most of Estrella Immunopharma's value examination focuses on studying past and present price action to predict the probability of Estrella Immunopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Estrella Immunopharma's price. Additionally, you may evaluate how the addition of Estrella Immunopharma to your portfolios can decrease your overall portfolio volatility.